Beam Therapeutics
BEAM
194 hedge funds and large institutions have $1.62B invested in Beam Therapeutics in 2023 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 79 increasing their positions, 39 reducing their positions, and 30 closing their positions.
103% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 39
35% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $12.2M
10% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 30
0.9% more ownership
Funds ownership: 84.24% → 85.14% (+0.9%)
0% more funds holding
Funds holding: 194 → 194 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less capital invested
Capital invested by funds: $2.05B → $1.62B (-$428M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$27.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$23M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.9M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$12.1M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.2M |
| 2 |
Morgan Stanley
New York
|
-$8.39M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$8.09M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$8.04M |
| 5 |
Goldman Sachs
New York
|
-$7.09M |
BEAM Hedge Fund Activity: Q3 2023 in Review
194 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q3 2023, worth a combined $1.62B — down 21% from $2.05B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new BEAM positions and 30 closed out — a net gain of 3 holders — while 79 added to existing stakes and 39 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $27.9M. The largest seller was Fidelity Investments, cutting an estimated $17.2M.
- 194 institutional investors held Beam Therapeutics (BEAM) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $1.62B of Beam Therapeutics stock for Q3 2023, down 21% quarter-over-quarter.
- 33 funds opened new Beam Therapeutics positions in Q3 2023 and 30 closed out, a net change of +3 holders.
- The largest Beam Therapeutics buyer in Q3 2023 was Farallon Capital Management, an estimated $27.9M added.
- The largest Beam Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $17.2M sold.
Based on aggregated 13F filings for Q3 2023.